Search Results for "Metastatic Her2 Breast Cancer Survival Rates"
Original Source: Revolutionary new cancer targeting technology described in Nature Medicine
(Oxford, UK, 6th May 2012) A revolutionary cancer-targeting technology developed by researchers at Immunocore Limited has been described for the first time in the prestigious medical journal, Nature Medicine. The new reagents known as ImmTACs (Immune Mobilising mTCR against Cancer) mobilise T cells to kill cancer cells and overcome immune tolerance to cancer. The most advanced of Immunocore’s ImmTACs, a drug called IMCgp100, is already in clinical trials in the UK and US for the treatm...
Matching Channels
The humanized anti-Her2 monoclonal antibody Herceptin (trastuzumab) has become the mainstay in the treatment of Her2-positive breast cancer. Combining trastuzumab with the potent cytotoxic DM1 via a s...
Targeted treatment of Her2-positive breast cancer with the anti-Her2 antibody trastuzumab has become an example of successful personalized medicine. The commercial success of Herceptin (trastuzumab)...
Breast cancer in the UK is diagnosed in nearly 46,000 people each year, with just over 12,000 dying from breast cancer each year in he UK. There are several risk factors for developing b...
Kadcyla (ado-trastuzumab emtansine)
Kadcyla™ (ado-trastuzumab emtansine or T-DM1) for the treatment of people with HER2-positive metastatic breast cancer (mBC) who have received prior treatment with Herceptin® (trastuzumab)...
Epithelial cell adhesion molecule EpCAM CD326
Epithelial cell adhesion molecule (EpCAM; CD326) is a cell surface protein that is frequently expressed at high level on most solid tumor types, including prostate, breast, colon, gastric, ovarian,...
Matching News
Dual targeting of metastatic breast cancer improves survival rates
A new study from the USC Norris Comprehensive Cancer Center showed that targeting both hormone receptors (HRs) and human epidermal growth factor receptor 2 (HER2) in first-line treatment of metastatic...
Kadcyla For Late-Stage Breast Cancer Approved By FDA
Kadcyla (ado-trastuzumab emtansine), a new medication for the treatment of HER2-positive, metastatic breast cancer, has been approved by the Food and Drug Administration (FDA), USA. Metastatic, also k...
Geron (GERN) Discontinues P2 Imetelstat clinical trial in metastatic HER2-negative breast cancer
On the basis of an unplanned interim analysis, it is discontinuing its randomized P2 study of imetelstat in metastatic HER2-negative breast cancer because median progression-free survival (PFS) in t...
Bevacizumab No Extra Help in Metastatic Breast Cancer
In metastatic breast cancer, adding bevacizumab to first-line chemotherapy improves progression-free survival (PFS) when tumors are HER2-negative - but not, as researchers just found out, when they're...
Targeted therapies: HER2-positive breast cancer—sifting through many good options
The addition of lapatinib to paclitaxel improves survival in patients with newly diagnosed HER2-positive metastatic breast cancer, further validating the importance of HER2 signalling as a target in t...
Roche obtains EU approval for new personalised breast cancer treatment
The EMA has approved Roche’s PERJETA (pertuzumab) for patients with previously untreated HER2-positive metastatic breast cancer (mBC). The treatment is approved in combination with Herceptin (trastu...
Roche insists Perjeta combo shows OS advantage in metastatic breast cancer
Roche/Genentech has said it has encouraging data on overall survival in HER2-positive metastatic breast cancer for the combination of its two HER2 targeted antibodies, Perjeta (pertuzumab) and Hercept...
Genentech's Perjeta boosts survival in breast cancer study
Genentech's breast cancer drug Perjeta, or pertuzumab, improved survival of patients with HER2-positive metastatic breast can -More-
Matching PubMed Articles
PURPOSE: High serum human epidermal growth factors receptor-2 (HER2) extracellular domain (ECD) has been identified as an independent prognostic indicator of poor prognosis in me...
Serum HER2 levels determined by two methods in patients with metastatic breast cancer.
BACKGROUND: The role and the optimal measurement method of serum HER2 levels are not defined in patients with metastatic breast cancer (MBC). We prospectively assessed the prognostic value of serum HE...
Sensitivity of CA 15-3, CEA and serum HER2 in the early detection of recurrence of breast cancer.
Abstract Background: The aim of this project was to investigate the sensitivity of CA 15-3, CEA and HER2 in the early diagnosis of metastatic breast cancer. Methods: Serial serum values of CA 15-3, CE...
There is a growing body of evidence that HER2 status can change during disease recurrence or progression in breast cancer patients. In this context, re-evaluation of HER2 status by assessment of HER2...
PURPOSE: The aim of this study was to determine whether estrogen receptor (ER)/progesterone receptor (PR) and human epidermal growth factor receptor type 2 (HER2) statuses betwee...
